The EU grants orphan drug status to Endocyte's (ECYT +2.1%) folic acid solution for helping to...

|By:, SA News Editor

The EU grants orphan drug status to Endocyte's (ECYT +2.1%) folic acid solution for helping to treat ovarian cancer. The solution is used as a pre-injection for the radiodiagnostic imaging agent, etarfolatide, to help select patients who can be treated with Endocyte's vintafolide drug, which it's developing with Merck and which is in Phase II and III cancer trials. (PR)